The effect of glucagon-like peptide 1 receptor agonists on brain structure in rat or mouse Alzheimer’s disease models: a Meta-analysis / 中华老年医学杂志

ABSTRACT

Objective:To systematically evaluate the effect of glucagon-like peptide 1 receptor agonists(GLP-1RA)on the brain structure of rat or mouse Alzheimer’s disease(AD)models.Methods:Data of randomized controlled trials from January 2000 to January 2018 for the effect of GLP-1RA on the brain structure of AD rats or mice were searched from all databases, including the Cochrane Library, EMbase, PubMed, Chinese Journal Full-text Database, the Chinese biomedical literature database, Chinese PSTP VIP and Wanfang database.Literature was selected based on inclusion and exclusion criteria defined in advance, and the quality was evaluated using the SYRCLE as animal experimental bias risk assessment tools.Valid data were retrieved and a meta-analysis was performed using the RevMan 5.3software.Results:A total of 9 articles with 207 rats and mice were included.Among the 207 cases, 123cases were in the experimental group and 84 cases in the control group.After treatment with GLP-1RA, there were significant differences in the amyloid plaque load[Low dose group mean difference(MD)=-5.55, 95% CI -6.92 to-4.17, P<0.01, High dose group MD=-4.81, 95% CI -6.63to-2.98, P<0.01], the amount of p-tau protein(MD=-3.16, 95% CI -4.29 to-2.02, P<0.01), and the activation of microglia in rat or mouse brain(liraglutide treatment group MD=-7.85, 95% CI -12.66 to-3.04, P<0.01, lixisenatide treatment group MD=-7.60, 95% CI -9.56 to-5.65, P<0.01)between the treatment group and the control group. Conclusions:GLP-1RA can reduce the amyloid plaque load, decrease the number of neurofibrillary tangles and inhibit the activation of microglia in the rat or mouse brain.